Options mapped

Mesothelioma: options by country

Sourced options by country plus visit-prep questions for Mesothelioma. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedSolid tumorLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

Is the disease localized, advanced, recurrent, pleural, peritoneal, or another site?
Is the goal disease-directed systemic therapy, surgery, symptom relief, or clinical-trial participation?
Which symptoms need supportive management now, such as effusion, pain, or breathing issues?
Is the MPM unresectable advanced or metastatic and untreated with systemic therapy in that setting?

Trial-search terms to discuss

Mesothelioma clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.
Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.
Pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [1]FDA-approvedNo biomarker requirement stated in fetched FDA approval notice; First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma; KEYNOTE-483 enrolled patients with no prior systemic therapy for advanced/metastatic disease. · FDA approval notice does not establish payer coverage, individual eligibility, or choice versus other first-line options. Confidence/conflicts: High for U.S. approval; no superiority claim over other first-line regimens.

European Union

Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.
Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.
Ipilimumab (Yervoy) with nivolumab (Opdivo); pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy [2]EMA authorisedNo biomarker requirement stated in fetched EMA product pages for the MPM indications; First-line adult unresectable MPM; Keytruda indication specifically non-epithelioid MPM per fetched EMA source. · EMA central authorization does not establish Germany/France reimbursement timing or local prescribing restrictions. Histology matters for the fetched Keytruda EU indication. Confidence/conflicts: High for EU indication text; member-state access remains to verify.

United Kingdom

Nivolumab (Opdivo) with ipilimumab (Yervoy)[3]ApprovedNo biomarker requirement stated in fetched NICE TA818 recommendation; Untreated unresectable malignant pleural mesothelioma in adults. · NICE recommendation is conditional on ECOG performance status and commercial arrangement. Devolved nation implementation and local pathway details may vary. Confidence/conflicts: High for NICE recommendation in specified population; local implementation still needs care-team confirmation.
Nivolumab (Opdivo) with ipilimumab (Yervoy)[3]ApprovedNo biomarker requirement stated in fetched NICE TA818 recommendation; Untreated unresectable malignant pleural mesothelioma in adults. · NICE recommendation is conditional on ECOG performance status and commercial arrangement. Devolved nation implementation and local pathway details may vary. Confidence/conflicts: High for NICE recommendation in specified population; local implementation still needs care-team confirmation.
Pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy [4]ApprovedNo biomarker requirement stated in fetched NICE TA1125 source; Untreated unresectable advanced malignant pleural mesothelioma in adults. · This is not a positive NICE recommendation. It does not establish routine NHS funding; local decision-making may apply if organisations consider the regimen. Confidence/conflicts: High for no NICE recommendation; conflict with U.S. FDA and EU EMA approvals is jurisdiction/access-specific.
Pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy [4]ApprovedNo biomarker requirement stated in fetched NICE TA1125 source; Untreated unresectable advanced malignant pleural mesothelioma in adults. · This is not a positive NICE recommendation. It does not establish routine NHS funding; local decision-making may apply if organisations consider the regimen. Confidence/conflicts: High for no NICE recommendation; conflict with U.S. FDA and EU EMA approvals is jurisdiction/access-specific.

Sources

U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
NICE — technology appraisal recommendation · technology appraisal recommendation
NICE — terminated technology appraisal advice · terminated technology appraisal advice

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiationClinical trialClinical trialReported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiationClinical trialClinical trialReported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiationClinical trialClinical trialReported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiationClinical trialClinical trialReported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiationClinical trialClinical trialReported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
Surgery; palliative pleurectomy/decortication; radiation therapy; first-line systemic therapy including nivolumab plus ipilimumab, cisplatin plus pemetrexed with or without bevacizumab, durvalumab with platinum plus pemetrexed, platinum plus pemetrexed with or without maintenance gemcitabine; symptomatic effusion management and palliative surgery/radiationClinical trialClinical trialReported in a clinical trialUnited States · No biomarker required by fetched NCI PDQ for listed standard modalities; Localized stage I; advanced stages II-IV; recurrent disease context for first-line systemic options if not previously received. · NCI PDQ is an evidence summary and not a payer, NCCN, or regulator source. Surgical and multimodality options are highly selected and should be discussed at a mesothelioma/thoracic oncology center. Confidence/conflicts: High for U.S. evidence-summary framework; exact regulator/reimbursement status recorded separately. National Cancer Institute (NCI) — national cancer agency evidence summary
Pembrolizumab with cisplatin and pemetrexed; nivolumab (Opdivo) with ipilimumab (Yervoy); rinatabart sesutecan with possible carboplatin/bevacizumab/pembrolizumab combination contextClinical trial · NCT04153565Clinical trialTrial only (registry)Japan · No biomarker required by fetched Japan registry records; Advanced MPM; unresectable advanced/recurrent MPM; advanced solid tumor study including mesothelioma. · Registry listing does not establish PMDA approval, reimbursement, routine access, current enrollment for completed studies, or individual eligibility. Confidence/conflicts: High for Japan registry-listed studies; approval/access remains unverified. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab with cisplatin and pemetrexed; nivolumab (Opdivo) with ipilimumab (Yervoy); rinatabart sesutecan with possible carboplatin/bevacizumab/pembrolizumab combination contextClinical trial · NCT04153565Clinical trialTrial only (registry)Japan · No biomarker required by fetched Japan registry records; Advanced MPM; unresectable advanced/recurrent MPM; advanced solid tumor study including mesothelioma. · Registry listing does not establish PMDA approval, reimbursement, routine access, current enrollment for completed studies, or individual eligibility. Confidence/conflicts: High for Japan registry-listed studies; approval/access remains unverified. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab with cisplatin and pemetrexed; nivolumab (Opdivo) with ipilimumab (Yervoy); rinatabart sesutecan with possible carboplatin/bevacizumab/pembrolizumab combination contextClinical trial · NCT04153565Clinical trialTrial only (registry)Japan · No biomarker required by fetched Japan registry records; Advanced MPM; unresectable advanced/recurrent MPM; advanced solid tumor study including mesothelioma. · Registry listing does not establish PMDA approval, reimbursement, routine access, current enrollment for completed studies, or individual eligibility. Confidence/conflicts: High for Japan registry-listed studies; approval/access remains unverified. ClinicalTrials.gov — clinical-trial registry
Pembrolizumab with cisplatin and pemetrexed; nivolumab (Opdivo) with ipilimumab (Yervoy); rinatabart sesutecan with possible carboplatin/bevacizumab/pembrolizumab combination contextClinical trial · NCT04153565Clinical trialTrial only (registry)Japan · No biomarker required by fetched Japan registry records; Advanced MPM; unresectable advanced/recurrent MPM; advanced solid tumor study including mesothelioma. · Registry listing does not establish PMDA approval, reimbursement, routine access, current enrollment for completed studies, or individual eligibility. Confidence/conflicts: High for Japan registry-listed studies; approval/access remains unverified. ClinicalTrials.gov — clinical-trial registry
Volrustomig; anetumab ravtansine (BAY94-9343) versus vinorelbine; tulmimetostat; KFA115 with pembrolizumab; NGM707 with pembrolizumabClinical trial · NCT06535607Clinical trialTrial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced/metastatic solid tumor including mesothelioma; second-line MPM for anetumab ravtansine record; unresectable pleural mesothelioma sub-study for volrustomig. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are broader solid-tumor baskets rather than mesothelioma-only studies. Confidence/conflicts: Medium-high for South Korea trial landscape; local approval status not established. ClinicalTrials.gov — clinical-trial registry
Volrustomig; anetumab ravtansine (BAY94-9343) versus vinorelbine; tulmimetostat; KFA115 with pembrolizumab; NGM707 with pembrolizumabClinical trial · NCT06535607Clinical trialTrial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced/metastatic solid tumor including mesothelioma; second-line MPM for anetumab ravtansine record; unresectable pleural mesothelioma sub-study for volrustomig. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are broader solid-tumor baskets rather than mesothelioma-only studies. Confidence/conflicts: Medium-high for South Korea trial landscape; local approval status not established. ClinicalTrials.gov — clinical-trial registry
Volrustomig; anetumab ravtansine (BAY94-9343) versus vinorelbine; tulmimetostat; KFA115 with pembrolizumab; NGM707 with pembrolizumabClinical trial · NCT06535607Clinical trialTrial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced/metastatic solid tumor including mesothelioma; second-line MPM for anetumab ravtansine record; unresectable pleural mesothelioma sub-study for volrustomig. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are broader solid-tumor baskets rather than mesothelioma-only studies. Confidence/conflicts: Medium-high for South Korea trial landscape; local approval status not established. ClinicalTrials.gov — clinical-trial registry
Volrustomig; anetumab ravtansine (BAY94-9343) versus vinorelbine; tulmimetostat; KFA115 with pembrolizumab; NGM707 with pembrolizumabClinical trial · NCT06535607Clinical trialTrial only (registry)Korea · No biomarker required by fetched Korea registry records; Advanced/metastatic solid tumor including mesothelioma; second-line MPM for anetumab ravtansine record; unresectable pleural mesothelioma sub-study for volrustomig. · Registry records do not establish MFDS approval, reimbursement, routine access, or individual eligibility. Some studies are broader solid-tumor baskets rather than mesothelioma-only studies. Confidence/conflicts: Medium-high for South Korea trial landscape; local approval status not established. ClinicalTrials.gov — clinical-trial registry
Sintilimab plus anlotinib plus pemetrexed/cisplatin; PM8002 with pemetrexed and platinum chemotherapy; alphaPD1-MSLN-CAR T cells; iparomlimab plus tovorilimab plus bevacizumab/pemetrexed/cisplatin; nivolumab plus ipilimumab versus pemetrexed/platinum; rinatabart sesutecanClinical trial · NCT05188859Clinical trialTrial only (registry)China · MSLN-positive required for alphaPD1-MSLN-CAR T-cell study; otherwise no biomarker requirement stated in fetched China registry records; First-line malignant pleural mesothelioma; unresectable pleural mesothelioma; MSLN-positive advanced solid tumors including mesothelioma; advanced solid tumors including mesothelioma. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some records are not-yet-recruiting or unknown-status. Confidence/conflicts: High for China registry-listed investigational options; regulatory access unverified. ClinicalTrials.gov — clinical-trial registry
Sintilimab plus anlotinib plus pemetrexed/cisplatin; PM8002 with pemetrexed and platinum chemotherapy; alphaPD1-MSLN-CAR T cells; iparomlimab plus tovorilimab plus bevacizumab/pemetrexed/cisplatin; nivolumab plus ipilimumab versus pemetrexed/platinum; rinatabart sesutecanClinical trial · NCT05188859Clinical trialTrial only (registry)China · MSLN-positive required for alphaPD1-MSLN-CAR T-cell study; otherwise no biomarker requirement stated in fetched China registry records; First-line malignant pleural mesothelioma; unresectable pleural mesothelioma; MSLN-positive advanced solid tumors including mesothelioma; advanced solid tumors including mesothelioma. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some records are not-yet-recruiting or unknown-status. Confidence/conflicts: High for China registry-listed investigational options; regulatory access unverified. ClinicalTrials.gov — clinical-trial registry
Sintilimab plus anlotinib plus pemetrexed/cisplatin; PM8002 with pemetrexed and platinum chemotherapy; alphaPD1-MSLN-CAR T cells; iparomlimab plus tovorilimab plus bevacizumab/pemetrexed/cisplatin; nivolumab plus ipilimumab versus pemetrexed/platinum; rinatabart sesutecanClinical trial · NCT05188859Clinical trialTrial only (registry)China · MSLN-positive required for alphaPD1-MSLN-CAR T-cell study; otherwise no biomarker requirement stated in fetched China registry records; First-line malignant pleural mesothelioma; unresectable pleural mesothelioma; MSLN-positive advanced solid tumors including mesothelioma; advanced solid tumors including mesothelioma. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some records are not-yet-recruiting or unknown-status. Confidence/conflicts: High for China registry-listed investigational options; regulatory access unverified. ClinicalTrials.gov — clinical-trial registry
Sintilimab plus anlotinib plus pemetrexed/cisplatin; PM8002 with pemetrexed and platinum chemotherapy; alphaPD1-MSLN-CAR T cells; iparomlimab plus tovorilimab plus bevacizumab/pemetrexed/cisplatin; nivolumab plus ipilimumab versus pemetrexed/platinum; rinatabart sesutecanClinical trial · NCT05188859Clinical trialTrial only (registry)China · MSLN-positive required for alphaPD1-MSLN-CAR T-cell study; otherwise no biomarker requirement stated in fetched China registry records; First-line malignant pleural mesothelioma; unresectable pleural mesothelioma; MSLN-positive advanced solid tumors including mesothelioma; advanced solid tumors including mesothelioma. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some records are not-yet-recruiting or unknown-status. Confidence/conflicts: High for China registry-listed investigational options; regulatory access unverified. ClinicalTrials.gov — clinical-trial registry
Sintilimab plus anlotinib plus pemetrexed/cisplatin; PM8002 with pemetrexed and platinum chemotherapy; alphaPD1-MSLN-CAR T cells; iparomlimab plus tovorilimab plus bevacizumab/pemetrexed/cisplatin; nivolumab plus ipilimumab versus pemetrexed/platinum; rinatabart sesutecanClinical trial · NCT05188859Clinical trialTrial only (registry)China · MSLN-positive required for alphaPD1-MSLN-CAR T-cell study; otherwise no biomarker requirement stated in fetched China registry records; First-line malignant pleural mesothelioma; unresectable pleural mesothelioma; MSLN-positive advanced solid tumors including mesothelioma; advanced solid tumors including mesothelioma. · Registry records do not establish NMPA approval, reimbursement, routine access, or individual eligibility. Some records are not-yet-recruiting or unknown-status. Confidence/conflicts: High for China registry-listed investigational options; regulatory access unverified. ClinicalTrials.gov — clinical-trial registry
PIPAC registry context; cosibelimab; NGR-hTNF maintenance plus best supportive care; nivolumab/ipilimumab versus pemetrexed/platinum; anetumab ravtansine versus vinorelbine; rAd-IFN with celecoxib and gemcitabine; tremelimumab; nintedanib with pemetrexed/cisplatinClinical trial · NCT03210298Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia registry records; Advanced MPM maintenance; first-line unresectable pleural mesothelioma; second-line MPM; unresectable pleural/peritoneal mesothelioma; registry context for PIPAC. · Registry records do not establish Russian regulatory approval, reimbursement, routine access, current enrollment, or individual eligibility. Some records are completed, terminated, unknown status, or registry rather than interventional treatment access. Confidence/conflicts: Medium-high for Russia registry landscape; current routine availability unverified. ClinicalTrials.gov — clinical-trial registry
PIPAC registry context; cosibelimab; NGR-hTNF maintenance plus best supportive care; nivolumab/ipilimumab versus pemetrexed/platinum; anetumab ravtansine versus vinorelbine; rAd-IFN with celecoxib and gemcitabine; tremelimumab; nintedanib with pemetrexed/cisplatinClinical trial · NCT03210298Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia registry records; Advanced MPM maintenance; first-line unresectable pleural mesothelioma; second-line MPM; unresectable pleural/peritoneal mesothelioma; registry context for PIPAC. · Registry records do not establish Russian regulatory approval, reimbursement, routine access, current enrollment, or individual eligibility. Some records are completed, terminated, unknown status, or registry rather than interventional treatment access. Confidence/conflicts: Medium-high for Russia registry landscape; current routine availability unverified. ClinicalTrials.gov — clinical-trial registry
PIPAC registry context; cosibelimab; NGR-hTNF maintenance plus best supportive care; nivolumab/ipilimumab versus pemetrexed/platinum; anetumab ravtansine versus vinorelbine; rAd-IFN with celecoxib and gemcitabine; tremelimumab; nintedanib with pemetrexed/cisplatinClinical trial · NCT03210298Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia registry records; Advanced MPM maintenance; first-line unresectable pleural mesothelioma; second-line MPM; unresectable pleural/peritoneal mesothelioma; registry context for PIPAC. · Registry records do not establish Russian regulatory approval, reimbursement, routine access, current enrollment, or individual eligibility. Some records are completed, terminated, unknown status, or registry rather than interventional treatment access. Confidence/conflicts: Medium-high for Russia registry landscape; current routine availability unverified. ClinicalTrials.gov — clinical-trial registry
PIPAC registry context; cosibelimab; NGR-hTNF maintenance plus best supportive care; nivolumab/ipilimumab versus pemetrexed/platinum; anetumab ravtansine versus vinorelbine; rAd-IFN with celecoxib and gemcitabine; tremelimumab; nintedanib with pemetrexed/cisplatinClinical trial · NCT03210298Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia registry records; Advanced MPM maintenance; first-line unresectable pleural mesothelioma; second-line MPM; unresectable pleural/peritoneal mesothelioma; registry context for PIPAC. · Registry records do not establish Russian regulatory approval, reimbursement, routine access, current enrollment, or individual eligibility. Some records are completed, terminated, unknown status, or registry rather than interventional treatment access. Confidence/conflicts: Medium-high for Russia registry landscape; current routine availability unverified. ClinicalTrials.gov — clinical-trial registry
PIPAC registry context; cosibelimab; NGR-hTNF maintenance plus best supportive care; nivolumab/ipilimumab versus pemetrexed/platinum; anetumab ravtansine versus vinorelbine; rAd-IFN with celecoxib and gemcitabine; tremelimumab; nintedanib with pemetrexed/cisplatinClinical trial · NCT03210298Clinical trialTrial only (registry)Russia · No biomarker requirement stated in fetched Russia registry records; Advanced MPM maintenance; first-line unresectable pleural mesothelioma; second-line MPM; unresectable pleural/peritoneal mesothelioma; registry context for PIPAC. · Registry records do not establish Russian regulatory approval, reimbursement, routine access, current enrollment, or individual eligibility. Some records are completed, terminated, unknown status, or registry rather than interventional treatment access. Confidence/conflicts: Medium-high for Russia registry landscape; current routine availability unverified. ClinicalTrials.gov — clinical-trial registry
Cosibelimab (CK-301)Clinical trial · NCT03212404Clinical trialTrial only (registry)Thailand · No biomarker requirement stated in fetched registry record; Advanced cancers including advanced malignant mesothelioma. · Registry listing does not establish Thai FDA approval, reimbursement, routine access, active enrollment at every site, or individual eligibility. Confidence/conflicts: Medium-high for Thailand registry listing; current access and local approval unverified. ClinicalTrials.gov — clinical-trial registry
Cosibelimab (CK-301)Clinical trial · NCT03212404Clinical trialTrial only (registry)Thailand · No biomarker requirement stated in fetched registry record; Advanced cancers including advanced malignant mesothelioma. · Registry listing does not establish Thai FDA approval, reimbursement, routine access, active enrollment at every site, or individual eligibility. Confidence/conflicts: Medium-high for Thailand registry listing; current access and local approval unverified. ClinicalTrials.gov — clinical-trial registry

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.